Intraductal meibomian gland probing and its efficacy in the treatment of meibomian gland dysfunction

• Published in: Survey of ophthalmology 2021-07, Vol.66 (4), p.612-622
• Main Authors: Magno, Morten, Moschowits, Emily, Arita, Reiko, Vehof, Jelle, Utheim, Tor Paaske
• Format: Article
• Language: English
• Subjects: dry eye disease; Dry Eye Syndromes; evaporative dry eye; Eyelid Diseases - surgery; Humans; Maskin probe; meibomian gland dysfunction; Meibomian Gland Dysfunction - therapy; meibomian gland probing; Meibomian Glands; Tears
• ISSN: 0039-6257; 1879-3304
• DOI: 10.1016/j.survophthal.2020.11.005

Meibomian gland dysfunction (MGD) is a major cause of dry eye, affecting millions worldwide. Intraductal meibomian gland probing (MGP) aims to open obstructed meibomian glands using a small probe to promote meibum secretion. MGP has received increasing interest since 2010, and we critically evaluated the literature on the efficacy and safety of MGP. Despite positive results of MGP on dry eye symptoms in early single-group studies, MGP was not shown to consistently outperform controls in later controlled trials. Furthermore, MGP alone did not show improvement beyond placebo in the only placebo-controlled RCT conducted. Overall, the procedure appears safe. Self-limited intraoperative bleeding was frequent, but no major complications were reported. In conclusion, MGP has not yet been shown to be an effective treatment for MGD. Larger placebo-controlled trials need to be conducted to establish the potential effect of this novel treatment modality.